Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 21, 2009

Antigen Discovery Scores $1.8M from NIAID to Develop Chlamydia Vaccine

  • Antigen Discovery was awarded $1.8 million from NIAID under the American Recovery and Reinvestment Act of 2009. The phase 2 STTR grant will fund efforts to further test and validate novel candidate antigens discovered during the company’s STTR phase 1 program. Antigen Discovery intends to develop the novel antigens as core protective components in a vaccine against chlamydia.

    The two-year grant supplements a previously awarded phase 2 STTR to the company in 2007. Antigen Discovery will collaborate with investigators in the department of pathology & laboratory medicine of the School of Medicine at the University of California, Irvine.

    “Antigen Discovery’s high-throughput proteomics approach has allowed us, for the first time, to successfully scan the entire proteome of Chlamydia trachomatis,” says Dr. Luis de la Maza, principal investigator on the STTR grant. “Our goal for this phase of the project is to identify a small subset of recombinant chlamydial antigens that induce strong protection against infection challenge. These antigens will be ideal candidates to develop a novel chlamydia vaccine."


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »